Rituximab Duration and Dosing in Myasthenia Gravis
For myasthenia gravis, initiate rituximab with 375 mg/m² weekly for 4 doses (or 1000 mg on days 1 and 15), followed by maintenance dosing of 500 mg every 6 months, guided by CD20+ B-cell monitoring rather than fixed schedules.
Initial Induction Regimen
The FDA-approved dosing for rituximab induction consists of 1:
- 375 mg/m² IV weekly for 4 consecutive weeks (days 1,8,15,22), OR
- 1000 mg IV on day 1 and day 15 (2-week interval)
Both regimens achieve B-cell depletion, though evidence suggests the extended 4-week protocol may provide superior durability. In anti-MuSK MG specifically, the "4+2 protocol" (375 mg/m² weekly for 4 weeks, then monthly for 2 additional months) demonstrated significantly lower relapse rates (18.2%) compared to the 1+1 protocol (80% relapse rate) over 5 years of follow-up 2. The hazard ratio for relapse with 1+1 versus 4+2 was 112.8 (95% CI 5.7-2250.4, p=0.002), representing dramatically inferior outcomes with abbreviated dosing.
Maintenance Therapy Duration and Schedule
Maintenance dosing should be 500 mg IV every 6 months, with treatment guided by CD20+ B-cell recovery rather than arbitrary time intervals 1. This approach is supported by:
- B-cell recovery typically occurs 9-30 months post-induction (median 12.3 months) and consistently correlates with symptom worsening 3
- CD20+ B-cell-guided retreatment (administering rituximab when CD20+ cells exceed 1%) showed excellent long-term efficacy over 48.5 months median follow-up, with 95.45% of patients achieving improved status 4
- Fixed 6-month maintenance intervals in vasculitis studies (which inform MG practice) demonstrated sustained remission 1
Treatment Duration
Continue rituximab for a minimum of 18-24 months after achieving remission, with many patients requiring longer-term therapy. The evidence shows:
- 89% of new-onset generalized MG patients remained relapse-free at 51.3 months mean follow-up with continued low-dose rituximab 5
- Long-term studies extending beyond 4 years demonstrate sustained benefit with ongoing maintenance 4
- Only 8 of 22 patients (36%) in one series could safely discontinue rituximab after achieving excellent disease control 4
Discontinuation should only be attempted after:
- Achieving minimal manifestations or better for ≥12 months
- Successful steroid taper to ≤10 mg daily or complete discontinuation
- Stable or undetectable antibody titers (though this doesn't always correlate with clinical status)
- Close monitoring for B-cell recovery and symptom recurrence
Serotype-Specific Considerations
Anti-MuSK MG responds dramatically better to rituximab than AChR+ disease:
- 72% of MuSK+ patients achieved minimal manifestations or better versus only 30% of AChR+ patients 6
- MuSK+ patients showed 82% antibody titer reduction versus 26% in AChR+ patients 6
- Consider more aggressive maintenance in AChR+ patients given higher relapse risk
Monitoring Strategy
Monitor every 3-6 months during maintenance:
- CD20+ B-cell counts (retreat when >1% or at clinical worsening)
- Clinical severity scores (QMG, MG-ADL)
- Antibody titers (though clinical status takes precedence)
- IgG levels (hypogammaglobulinemia occurred in 27-58% of patients) 1
Critical Safety Considerations
- Infusion reactions occur in 12-32% after first infusion, decreasing to <4% with subsequent doses 1
- Premedicate with antihistamine, acetaminophen, and methylprednisolone
- Serious infections occur in 11-28% of patients; monitor closely 1
- Hypogammaglobulinemia develops in up to 58% of patients; consider IVIG supplementation if IgG <3 g/L with recurrent severe infections 7
Corticosteroid Co-Administration
Rituximab can be used as monotherapy without corticosteroids in new-onset MG 8. Recent evidence shows rituximab alone achieved equivalent outcomes to rituximab plus steroids (Osserman scores 86.6 vs 88.69 at 12 months, p=0.761), with significantly fewer rescue therapy requirements (20.41% vs 47.37%, p=0.037) 8. This challenges traditional practice and suggests avoiding steroids when possible to minimize side effects.
The 2025 ABN guidelines now support early rituximab use within 1 year of generalized disease onset 9, representing a paradigm shift toward earlier B-cell depletion therapy rather than prolonged conventional immunosuppression.